The 9th Vaccine Industry Excellence (ViE) Awards provide a time and a place to celebrate the industry’s most outstanding achievements.
The awards are positioned to identify and reward those organizations and individuals who have demonstrated an unparalleled ability
to succeed and to continually set standards of excellence and advocacy over the previous 12 months.
December 11, 2015
January 22nd, 2016
February 1st, 2016
February 7th, 2016
March 1, 2016
March 29, 2016
Nominations are open
Nominations close
Shortlisted companies contacted for award submission document
Shortlist announced publicly and online shortlist voting opens
Award submissions provided to Scientific Advisory Board & online voting closes
Winners are announced at the 9th ViE Awards Ceremony & Gala Dinner
The ViE Awards prides itself on its judging panel composed of the members of our scientific advisory board. Each of the jusdges, who are senior industry representatives from governmental organizations, academia, industry wide experts and affiliate member associations, pharmaceutical and biotech, are chosen for their knowledge, objectivity and credibility:
Dr Gregory A. Poland , Director of Mayo Vaccine Research Group, Mayo Clinic
Dr Cyril Gay, Senior National Program Leader, Office of National Programs, USDA
Dr Michael Watson, VP Vaccination Policy & Advocacy, Sanofi Pasteur
Dr Bruce Gellin , Deputy Assistant Secretary for Health & Director, NVPO
Dr George Siber, Exec Director, Chair of Scientific Advisory Board, CSO, Genocea Biosciences Inc
Dr Leonard Friedland, VP, Scientific Affairs and Public Health Vaccines, North America, GSK
Dr Luis Jodar, Vice President, Vaccines, Global, Medicines Development group and Scientific Affairs, Pfizer
Notation: At the end of the submission period, ending on January 22nd, the board will receive a copy of each submission per award category.
Each judge, will be requested to mark each submission form against each criteria. The score for each category will range between 0 and 10. Scores are then collated by the ViE Awards team. The organization, team or person collecting the maximum number of points per category will be the winner of the awards. A strict embargo on results will be imposed and the results will only be revealed during the evening Awards ceremony on March 29, 2016.
DOWNLOAD AWARDS CRITERIA AND SUBMISSION INFORMATION HERE
The Best Clinical Trial Site OR Network category is open to international trial sites and their network owners
> Matching clinical development needs through a complete programmatic assessment
> Supportive of multiple and diverse clinical phase and outcomes trials for vaccines
> Methods of performance improvement or introduction of new services
> Rapid enrolment across a variety of vaccine ranges and outstanding study subject retention
> Reaching of milestones and final / ongoing outcomes / trials
The Best Contract Research Organization category is open to international CROs
> The range of services provided in niche and core therapeutic areas
> Methods of performance improvement or introduction of new services
> Attention to and quality of relationships with clients
> Reaching of milestones and final / ongoing outcomes
> Building and maintaining existing and long-term partnerships
The Best Contract Manufacturing Organization category is open to international CMOs
> The range of services provided in niche and core therapeutic areas
> Methods of performance improvement or introduction of new services
> Attention to and quality of relationships with clients
> Reaching of milestones and final / ongoing outcomes
> Building and maintaining existing and long-term partnerships
Best Production/Process Development
> Demonstration of an ongoing commitment to provide production or process technology globally and in reducing lead times for its customers
> Demonstration of an end-to-end suite of solutions to customers
> Demonstration of outstanding thought leadership in spearheading innovation
> Examples of raising the bar of process or production standards
> Attention to and quality of relationships with clients
The Best Academic Research Team category is open to research institutes and universities
> Candidates addressing current unmet medical needs
> Significant potential for vast geographical and market reach
> Research possession of a novel mode of action or technology
> Progress through pre- / clinical phases and / or study results achieved
> Details of significant grants ie. donors / amounts achieved supporting research
The Best Early-Stage Vaccine Biotech category is open to global early-stage Biotechs
> Ability to move the business from early stage to a more mature company
> Quality and diversity of the vaccine pipeline and candidates
> Advancements in taking a new product to market or through clinical stages
> Meaningful licensing or partnership deals
> Securing significant new funds for growth
The Biotech CEO of the Year category is open to Chief Executives from all sized Biotechs
>
Degree of outstanding commitment to disease prevention and treatment
> Level of exemplary leadership throughout the year
> Contribution to company performance, communication and vision
> Influence within the industry and communication of a shared vision
> Achievements made with regards to company positioning and status
The Best Pharma Company category is open to international Pharmaceutical organizations
> Size and range of the overall vaccine pipeline
> Mix across development phases
> Spread across innovation and lower risk candidate development
> Commitment to R&D productivity model implementation
> Current and future market potential and value for the pipeline
The Best Therapeutic Vaccine (approved or in development) category is open to all vaccine organizations
> Vaccine candidate addresses current unmet medical needs
> Candidate shows significant potential for vast geographical and market reach
> Candidate possesses a novel mode of action or technology
> Progress made to-date through clinical trials and / or achieved milestones
> Advanced efficacy, safety and risk management data where appropriate
The Best Prophylactic Vaccine (approved or in development) category is open to all vaccine organizations
> Vaccine candidate addresses current unmet medical needs
> Candidate shows significant potential for vast geographical and market reach
> Candidate possesses a novel mode of action or technology
> Progress made to-date through clinical trials and / or achieved milestones
> Advanced efficacy, safety and risk management data where appropriate